Highlights
- EPS (TTM)
- -$15.79
- Total Revenue (TTM)
- $6.78M
- Gross Profit (TTM)
- $1.62M
- EBITDA (TTM)
- -$14.11M
- Year Range
- $0.05 - $0.81
- ROA (TTM)
- -134.47%
- ROE (TTM)
- -202.53%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in bioAffinity Technologies Inc. Warrant, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
bioAffinity Technologies Inc. Warrant (BIAFW) has returned 29.29% so far this year and 138.28% over the past 12 months.
bioAffinity Technologies Inc. Warrant
- 1D
- 50.83%
- 1M
- 61.61%
- YTD
- 29.29%
- 6M
- 37.12%
- 1Y
- 138.28%
- 3Y*
- 14.68%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 1, 2022, BIAFW's average daily return is +1.81%, while the average monthly return is +16.19%. At this rate, your investment would double in approximately 0.4 years.
Historically, 47% of months were positive and 53% were negative. The best month was Sep 2025 with a return of +371.4%, while the worst month was Sep 2022 at -83.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BIAFW closed higher 27% of trading days. The best single day was Sep 26, 2025 with a return of +244.8%, while the worst single day was Oct 17, 2023 at -63.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.43% | -9.68% | 61.61% | 29.29% | |||||||||
| 2025 | 78.36% | -32.50% | -53.11% | -9.90% | 5.20% | -27.78% | 23.08% | -56.25% | 371.43% | 42.42% | -42.55% | 29.63% | 4.04% |
| 2024 | 19.65% | 86.59% | 298.65% | -52.97% | -33.33% | 25.21% | 83.03% | 116.36% | -3.36% | -31.99% | -8.00% | -53.25% | 291.16% |
| 2023 | 7.14% | -24.44% | -11.76% | -25.97% | 21.91% | 89.46% | -14.23% | -34.09% | -68.55% | 20.61% | 9.09% | -28.33% | -79.52% |
| 2022 | -83.13% | 33.19% | 6.78% | -16.65% | -80.00% |
Benchmark Metrics
bioAffinity Technologies Inc. Warrant has an annualized alpha of 7227.56%, beta of 1.57, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 02, 2022.
- This stock captured 1173.28% of S&P 500 Index gains and 301.66% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 7,227.56%
- Beta
- 1.57
- R²
- 0.01
- Upside Capture
- 1,173.28%
- Downside Capture
- 301.66%
Return for Risk
Risk / Return Rank
BIAFW ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for bioAffinity Technologies Inc. Warrant (BIAFW) and compare them to a chosen benchmark (S&P 500 Index).
| BIAFW | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.35 | 0.90 | -0.55 |
Sortino ratioReturn per unit of downside risk | 4.08 | 1.39 | +2.70 |
Omega ratioGain probability vs. loss probability | 1.68 | 1.21 | +0.46 |
Calmar ratioReturn relative to maximum drawdown | 1.32 | 1.40 | -0.08 |
Martin ratioReturn relative to average drawdown | 2.03 | 6.61 | -4.58 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BIAFW risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the bioAffinity Technologies Inc. Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the bioAffinity Technologies Inc. Warrant was 97.57%, occurring on Oct 9, 2023. The portfolio has not yet recovered.
The current bioAffinity Technologies Inc. Warrant drawdown is 78.45%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.57% | Sep 2, 2022 | 276 | Oct 9, 2023 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of bioAffinity Technologies Inc. Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how bioAffinity Technologies Inc. Warrant is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BIAFW relative to other companies in the Diagnostics & Research industry. Currently, BIAFW has a P/S ratio of 0.1. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |